4种化疗方案治疗Ⅲb～Ⅳ期非小细胞肺癌的最小成本分析  

Cost-minimization Analysis of 4 Chemotherapies for Advanced (Ⅲb～Ⅳ) Non-small Cell Lung Cancer

作　　者：郭红[1] 徐红[1] 张秀明[1] 李文菁[1] 

机构地区：[1]解放军总医院药品保障中心,北京市100853

出　　处：《中国药房》2008年第14期1051-1053,共3页China Pharmacy

摘　　要：目的:评价术后复发转移和局部晚期的非小细胞肺癌4种化疗方案的成本-效果。方法:74例术后复发转移和局部晚期的非小细胞肺癌化疗患者分为PC、GP、NP、TC组,治疗2个周期评价疗效和进行成本-效果分析。结果:4组成本分别为15679.72、10688.00、7665.98、13627.38元,有效率分别为40.00%、40.91%、38.46%、42.11%(P>0.05)。不良反应为不同程度的骨髓抑制、血小板变化、恶心呕吐、脱发等,经对症治疗均痊愈。结论:NP组成本较低,但此方案的不良反应较重;如患者经济条件好,重视生活质量,可选用GP方案。OBJECTIVE： To evaluate the cost - effectiveness of four chemotherapies on postoperative relapse and metastasis and local advanced Non-small Cell Lung Cancer （NSCLC） . METHODS： 74 patients with postoperative relapse and metastasis and local advanced NSCLC were assigned to PC, GP, NP or TC groups. The curative effects and the cost- effectiveness were evaluated after 2- week treatment. RESULTS： The costs for the 4 groups were 15 679.72 yuan, 10 688.00 yuan, 7 665.98 yuan, and 13 627.38 yuan, respectively; the effective rates were 40.00%, 40.91%, 38.46%, and 42.11% （P〉0.05）, respectively. The adverse drug reactions （ADR） were characterized by different degree of myelosuppression, change in platelet, nausea and vomiting, alopecia etc, all were cured with symptomatic treatment. CONCLUSION： NP scheme enjoys good cost- effectiveness, but with severe ADR. For those patients had good economical condition and attach great importance to life quality,GP scheme is preferable.

关 键 词：非小细胞肺癌 化疗方案 最小成本分析 

分 类 号：R956[医药卫生—药学] R979.1